CONCORD

Concord Drugs Share Price

 

 

Start SIP in CONCORD

Start SIP

Performance

  • Low
  • ₹0
  • High
  • ₹0
  • 52 Week Low
  • ₹0
  • 52 Week High
  • ₹0
  • Open Price₹0
  • Previous Close₹0
  • Volume
  • 50 DMA₹80.05
  • 100 DMA₹73.02
  • 200 DMA₹62.49

Investment Returns

  • Over 1 Month + 1.2%
  • Over 3 Month + 20.66%
  • Over 6 Month + 27.71%
  • Over 1 Year + 123.37%

Smart Investing Starts Here Start SIP with Concord Drugs for Steady Growth!

Invest Now

Concord Drugs Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

Concord Drugs Financials

Concord Drugs Technicals

EMA & SMA

Current Price
₹82.00
-1.06 (-1.28%)
  • Bearish Moving Average 0
  • Bullish Moving Average 0
  • 20 Day
  • ₹83.73
  • 50 Day
  • ₹80.05
  • 100 Day
  • ₹73.02
  • 200 Day
  • ₹62.49

Resistance and Support

81.09 Pivot Speed
  • R3 88.02
  • R2 85.95
  • R1 83.16
  • S1 78.30
  • S2 76.23
  • S3 73.44

Concord Drugs Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-13 Quarterly Results
2025-08-08 Quarterly Results
2025-07-03 Preferential issue of shares
2025-06-27 Preferential Issue of shares & Others Inter-alia, to consider 1. the date, time, and venue for convening an ExtraOrdinary General Meeting of the Company. 2. Other business matters.
2025-05-23 Audited Results

Concord Drugs F&O

Concord Drugs Shareholding Pattern

Concord Drugs FAQs

Concord Drugs share price is ₹82 As on 12 January, 2026 | 21:50

The Market Cap of Concord Drugs is ₹108 Cr As on 12 January, 2026 | 21:50

The P/E ratio of Concord Drugs is 187.7 As on 12 January, 2026 | 21:50

The PB ratio of Concord Drugs is 2.9 As on 12 January, 2026 | 21:50

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23